PTC Therapeutics price target lowered to $66 from $68 at Cantor Fitzgerald

Cantor Fitzgerald lowered the firm’s price target on PTC Therapeutics to $66 from $68 and keeps an Overweight rating on the shares. There were few surprises on the annual revenues/2023 financial guidance given the company recently reported unaudited metrics around a conference in January, and while there were some slight timeline shifts around the pivotal trial readouts, the company definitively stated when last patient last visits would take place, the analyst tells investors in a research note.